NVLN Logo.jpg
Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
30. August 2019 08:02 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press...
NVLN Logo.jpg
Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
21. August 2019 17:09 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press...
NVLN Logo.jpg
Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
12. August 2019 16:34 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
NVLN Logo.jpg
Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
16. Juli 2019 18:43 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 16, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Receives Delisting Notifications
05. Juli 2019 08:30 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Responds to Whitefort Capital Petition
24. Juni 2019 08:30 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, June 24, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
20. Mai 2019 22:53 ET | Novelion Therapeutics, Inc.
Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of DirectorsAegerion will continue to make available to...
NVLN Logo.jpg
Novelion Therapeutics Reports First Quarter 2019 Financial Results
07. Mai 2019 16:01 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing...
NVLN Logo.jpg
Novelion Therapeutics Observes World Lipodystrophy Day
31. März 2019 02:00 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 31, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
NVLN Logo.jpg
Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
14. März 2019 17:12 ET | Novelion Therapeutics, Inc.
Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and CAMBRIDGE, Mass., March 14, 2019 (GLOBE...